Related Experiment Video
Updated: Aug 5, 2026
08:07
Establishment of an Experimental Mouse Model of Endometrioma to Study its Related Infertility
Published on: April 5, 2024
Nanomaterial Platforms for Endometriosis: A Systematic Review
Hong-Yu Chen1,2, Na Li3,2, Xiao-Dan Zhu1
1Department of Gynecology, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, 250021, China.
Current Medical Science
|July 30, 2026
Summary
Nanotechnology offers a promising approach for treating endometriosis (EM) by delivering drugs directly to affected tissues. This review compares hydrogels, extracellular vesicles, and nanoparticles for their potential in managing EM inflammation, fibrosis, and angiogenesis.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Reproductive Medicine
Background:
- Endometriosis (EM) is a prevalent, estrogen-dependent inflammatory condition impacting 10% of reproductive-age women globally.
- EM causes severe pelvic pain, infertility, and reduced quality of life, with current treatments facing limitations like systemic side effects and high recurrence rates.
- Nanotechnology-based drug delivery presents a novel strategy to target therapeutic agents to EM lesions, potentially minimizing systemic toxicity.
Purpose of the Study:
- To systematically review and compare three nanomaterial platforms for endometriosis treatment: hydrogels, extracellular vesicles (EVs), and inorganic nanoparticles.
- To analyze the physicochemical properties, therapeutic rationale, and preclinical outcomes of each platform.
- To evaluate how each nanocarrier strategy addresses key pathological processes in endometriosis, including inflammation, fibrosis, and angiogenesis.
Main Methods:
- Systematic literature review of nanomaterial platforms for endometriosis.
- Analysis of physicochemical properties, therapeutic rationale, and preclinical data.
- Comparative assessment of hydrogels, EVs, and inorganic nanoparticles in addressing EM pathology.
Main Results:
- Hydrogels, EVs, and inorganic nanoparticles show potential for targeted drug delivery in EM.
- Each platform exhibits unique strengths and limitations regarding drug loading, release kinetics, and biocompatibility.
- Preclinical data suggest these nanomaterials can modulate inflammation, fibrosis, and angiogenesis in EM models.
Conclusions:
- Nanomaterial-based drug delivery systems offer a promising avenue for improved endometriosis therapeutics.
- Further research is needed to optimize nanocarrier design and address limitations for successful clinical translation.
- This review provides a framework for comparing nanocarrier strategies to advance endometriosis treatment development.
